We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+12.08%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.21B
AUM Growth
+$265M
Cap. Flow
+$241M
Cap. Flow %
19.9%
Top 10 Hldgs %
61.52%
Holding
77
New
29
Increased
17
Reduced
10
Closed
19

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$162M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$52.5M
3
ONC
BeOne Medicines Ltd
ONC
+$52.3M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$45.9M
5
NARI
Inari Medical, Inc. Common Stock
NARI
+$42.7M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$58.1M
2
MRK icon
Merck
MRK
+$43.6M
3
CBAY
Cymabay Therapeutics
CBAY
+$38.4M
4
PCRX icon
Pacira BioSciences
PCRX
+$34.4M
5
PCVX icon
Vaxcyte
PCVX
+$33M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
76
DELISTED
Cymabay Therapeutics
CBAY
– –
-1,625,000
Closed -$38.4M
INBX
77
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-1,530,000
Closed -$58.1M
1 2 3
4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $3.52B AUM 52.63% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Vestal Point Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Vestal Point Capital held 77 positions worth $1.21B, up 28% from $944M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Vestal Point Capital deployed $241M of net new capital in Q1 2024, opening 29 new positions and adding to 17 existing holdings. Its largest new stake was BeOne Medicines Ltd: 325,000 shares worth $50.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Pacira BioSciences, an estimated $34.4M trimmed.

  • Vestal Point Capital's largest Q1 2024 buy was BeOne Medicines Ltd: 325,000 shares worth $50.8M.
  • Vestal Point Capital added most to Cytokinetics in Q1 2024, an estimated $162M increase.
  • Vestal Point Capital's biggest Q1 2024 reduction was Pacira BioSciences, cutting an estimated $34.4M.
  • Vestal Point Capital fully exited Inhibrx, Inc. Common Stock in Q1 2024, selling an estimated $58.1M.
  • Vestal Point Capital's ten largest holdings make up 62% of its $1.21B portfolio in Q1 2024.
  • Vestal Point Capital opened 29 new positions and closed 19 in Q1 2024.
  • Vestal Point Capital's portfolio value rose 28% quarter-over-quarter to $1.21B.

Based on Vestal Point Capital's 13F filing for Q1 2024, filed 14 May 2024.